ALTILIX™ is a powder extract obtained from the leaves of a particular cultivar named Cynara cardunculus var. Altilis DC, by using aqueous extraction methods.
BIONAP has selected this specific cultivar because of its high concentration of biophenols and its resistance to severe weather conditions.
Metabolic syndrome is defined as the coexistance of several risk factors of metabolic origin including high blood sugar, obesity, increases blood pressure, high cholesterol and non-alcoholic fatty liver disease (NAFLD). The prevalence of NAFLD can reach 90% in obese and hyperlipidemic subjects. Despite its growing clinical burden, there are no specific drug for the treatment of these subjects and their management is necessarily related to lifestyle changes.
ALTILIX™ is the innovative natural ingredient for liver detoxification and NAFLD.
Cynara cardunculus (L.) or artichoke is native to the Mediterranean region. The edible parts of artichoke have important nutritional value and are used in the Mediterranean folk medicine thanks to its multiple health benefit like liver detoxification and gastro-intestinal well-being.
Bioactive compounds contained in ALTILIX™ have been shown to have liver detoxification, glucose management and vascular protection activities. These functions improve bile formation and insulin resistance. The flavonoids contained in artichoke leaves have shown to inhibit cholesterol biosynthesis and LDL oxidation.
In vitro studies has shown that ALTILIX™ can counteract fat accumulation in hepatocytes cell line induced by free fatty acid.
The activity of ALTILIX™ has been evaluated in a randomized, double-blind, placebo-controlled clinical trial carried out:
• on 100 volunteers with metabolic syndrome at 3 different level of NAFLD
• treated with 150 mg/day of ALTILIX™
• for 6 months
ALTILIX™ supplementation showed statistically significant improvement of NAFLD (Fatty Liver Index) and other evaluated parameters including hepatic enzymes (AST, ALT, AST/ALT ratio), glucose metabolism parameters (HbA1c, HOMA-IR and HOMA-β), lipid profile (TC, TG and LDL-C), flow mediated dialation and Carotid intima-media thickness (cIMT).
SIGNIFICANT IMPROVEMENT OF HEPATIC AND CARDIOMETABOLIC PARAMETERS